Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Bioasis Technologies Inc (OP: BIOAF )

0.0001 UNCHANGED
Last Price Updated: 9:31 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0001
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0001
Today's Range 0.0001 - 0.0001
52wk Range 0.0001 - 0.0130
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bioasis Provides Corporate Update and Announces Suspension of Operations
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Provides Update on Business Operations
From Bioasis Technologies Inc.
Via GlobeNewswire

Performance

YTD
-97.92%
-97.92%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-95.83%
-95.83%

More News

Read More
Bioasis Announces AGM Results and Provides Update on Financial Position
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Technologies Inc. Announces Shareholder Webinar
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
From Bioasis Technologies Inc.
Via GlobeNewswire
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
From Bioasis Technologies Inc.
Via GlobeNewswire
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Bioasis Technologies’ xB3 Platform Unlocks Revolutionary Neurological Disease Treatments
Via Get News
Bioasis Technologies Breaks through Blood-Brain Barrier with xB3 platform, Revolutionizing Neurological Disease Treatment
Via Get News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.